Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 11, Issue 2, pp. 308-316
PubMed
Published By
Print ISSN
Online ISSN
History
- Received July 25, 2011
- Revision received November 2, 2011
- Accepted December 1, 2011
- Published first December 27, 2011.
Article Versions
- Previous version (December 27, 2011 - 07:29).
- You are viewing the most recent version of this article.
Copyright & Usage
©2011 American Association for Cancer Research.
Author Information
- Razelle Kurzrock1,
- Nash Gabrail4,
- Chandtip Chandhasin1,
- Stacy Moulder2,
- Carrie Smith4,
- Andrew Brenner3,
- Kamalesh Sankhala3,
- Alain Mita3,
- Kelly Elian5,
- Danielle Bouchard5, and
- John Sarantopoulos3
- Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Program) and 2Breast Medical Oncology, MD Anderson Cancer Center, Houston, Texas; 3Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center San Antonio, San Antonio, Texas; 4Gabrail Cancer Center, Canton, Ohio; and 5Angiochem Inc., Montreal, Québec, Canada
- Corresponding Author:
Razelle Kurzrock, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-794-1226; Fax: 713-794-3249; E-mail: rkurzroc{at}mdanderson.org
February 2012
Volume 11, Issue 2
Volume 11, Issue 2
Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
Jump to section
Advertisement